var title_f26_40_27264="Uncovered biliary stent";
var content_f26_40_27264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uncovered biliary stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative photo of an uncovered biliary self-expanding metal stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas G. Adler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27264=[""].join("\n");
var outline_f26_40_27264=null;
var title_f26_40_27265="Flunisolide: Patient drug information";
var content_f26_40_27265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flunisolide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=see_link\">",
"       Flunisolide (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/49/34581?source=see_link\">",
"       Flunisolide (oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12478 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27265=[""].join("\n");
var outline_f26_40_27265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=related_link\">",
"      Flunisolide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/49/34581?source=related_link\">",
"      Flunisolide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_40_27266="Disease-modifying antirheumatic drugs (DMARDs)";
var content_f26_40_27266=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/40/27266/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27266/contributors\" id=\"au5724\">",
"       Peter H Schur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/40/27266/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27266/contributors\" id=\"se4268\">",
"       Daniel E Furst, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/40/27266/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27266/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?26/40/27266?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DISEASE-MODIFYING ANTIRHEUMATIC DRUG OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Disease-modifying antirheumatic drugs (DMARDs) are a group of medications commonly used in patients with rheumatoid arthritis. They work to decrease pain and inflammation, to reduce or prevent joint damage, and to preserve the structure and function of the joints. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"      \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT ARE DISEASE-MODIFYING ANTIRHEUMATIC DRUGS?",
"     </span>",
"    </p>",
"    <p>",
"     DMARDs work to suppress the body's overactive immune",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     inflammatory systems. They take effect over weeks or months and are not designed to provide immediate relief of symptoms.",
"    </p>",
"    <p>",
"     Other medicines, such as pain relievers, nonsteroidal antiinflammatory drugs (eg, ibuprofen or naproxen), and, sometimes, prednisone, are given to provide faster relief of ongoing symptoms. DMARDs are often used in combination with these medications to reduce the total amount of medication needed and to prevent damage to joints.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DISEASE-MODIFYING ANTIRHEUMATIC DRUGS",
"     </span>",
"    </p>",
"    <p>",
"     The choice of DMARD depends on a number of factors, including the stage and severity of the joint condition, the balance between possible side effects and expected benefits, and patient preference. Before treatment begins, the patient and clinician should discuss the benefits and risks of each type of therapy, including possible side effects and toxicities, dosing schedule, monitoring frequency, and expected results.",
"    </p>",
"    <p>",
"     In some cases, one DMARD is used. In others, more than one medication may be recommended. Sometimes a patient must try different medicines or combinations to find one that works best and that has the fewest side effects. A patient who does not respond completely to a single DMARD may be given a combination of DMARDs, such as methotrexate plus another medication.",
"    </p>",
"    <p>",
"     The most common DMARDs are methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide. Less frequently used medications include gold salts, azathioprine, and cyclosporine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Methotrexate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Methotrexate was originally used as a chemotherapy treatment for cancer. When used in much lower doses for rheumatoid arthritis and other rheumatic diseases, methotrexate works to reduce inflammation and to decrease joint damage. It is usually taken once per week as a pill, liquid, or injection. Methotrexate may be combined with other DMARDs or with a biologic agent if methotrexate alone does not adequately control a patient's disease. (See",
"     <a class=\"local\" href=\"#H17\">",
"      'Biologic agents'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Common side effects include upset stomach and a sore mouth. Methotrexate can interfere with the bone marrow's production of blood cells. Low blood cell counts can cause fever, infections, swollen lymph nodes, and easy bruisability and bleeding. Liver or lung damage can occur, even with low doses, and, therefore, requires monitoring. People using methotrexate are strongly discouraged from drinking alcoholic beverages because of the increased risk of liver damage with this combination.",
"    </p>",
"    <p>",
"     Monitoring reduces the risk of long-term damage from methotrexate. A chest x-ray is recommended before beginning treatment, and regular blood testing is recommended. While taking methotrexate, most patients take folic acid 1 mg daily or folinic acid 5 mg weekly to reduce the risk of certain side effects, such as upset stomach, sore mouth, low blood cell counts, and abnormal liver function.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Sulfasalazine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sulfasalazine is used in the treatment of rheumatoid arthritis and of arthritis associated with ankylosing spondylitis and inflammatory bowel disease (ulcerative colitis and Crohn&rsquo;s disease). It is not clear how sulfasalazine works. It may be combined with other DMARDs if a person does not respond adequately to one medication. It is taken as a pill two to four times per day, and it is usually started at a low dose and is increased slowly to minimize side effects.",
"    </p>",
"    <p>",
"     Side effects of sulfasalazine include changes in blood counts, nausea or vomiting, sensitivity to sunlight, skin rash, and headaches. People who are allergic to sulfa drugs may have a cross reaction to sulfasalazine and should, therefore, not take it. Periodic blood tests are recommended to monitor the blood count on a regular basis.",
"    </p>",
"    <p>",
"     Sulfasalazine is a",
"     <span class=\"nowrap\">",
"      yellow/orange",
"     </span>",
"     color; patients who take it may notice that their urine, tears, and sweat develop an orange tinge, which can stain clothing and contact lenses. Patients should drink plenty of fluids while taking sulfasalazine and should avoid taking it on an empty stomach or with antacids.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Hydroxychloroquine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hydroxychloroquine, originally developed as a treatment for malaria, was later found to improve symptoms of arthritis. It can be used early in the course of rheumatoid arthritis and is often used in combination with other DMARDs. It is also very frequently used for treatment of systemic lupus erythematosus. It can be combined with steroid medications to reduce the amount of steroid needed. It is usually taken in pill form once or twice per day.",
"    </p>",
"    <p>",
"     Taking a high dose of hydroxychloroquine for prolonged periods of time may increase the risk of damage to the retina of the eye, although high doses are not usually required for treatment of rheumatoid conditions or lupus. An eye examination is recommended before starting treatment and periodically thereafter. It is common to have an eye check-up done once each year.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Leflunomide",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leflunomide inhibits production of inflammatory cells to reduce inflammation. It is often used alone but may be used in combination with methotrexate for people who have not responded adequately to methotrexate alone or together with a biologic agent. It is taken by mouth once daily.",
"    </p>",
"    <p>",
"     Side effects include rash, temporary hair loss, liver damage, nausea, diarrhea, weight loss, and abdominal pain. Regular testing to monitor for liver damage is required.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Azathioprine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Azathioprine (AZA) has been used in the treatment of cancer, rheumatoid arthritis, lupus, and a variety of other inflammatory illnesses since the 1950s. It has also been used in organ transplantation to prevent rejection of the transplanted organ. AZA is generally reserved for patients who have not responded to other treatments.",
"    </p>",
"    <p>",
"     The most common side effects of AZA include nausea, vomiting, decreased appetite, liver function abnormalities, low white blood cell counts, and infection. It is usually taken by mouth once to four times daily. Blood testing is recommended during treatment with AZA.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H34829244\">",
"     <span class=\"h2\">",
"      Cyclosporine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cyclosporine was originally developed to prevent rejection after organ transplantation. It works in patients with rheumatoid arthritis to inhibit T lymphocytes, a cell that contributes to the inflammation associated with rheumatoid arthritis. There is concern about the long-term safety of cyclosporine and its association with kidney disease and high blood pressure, so it is generally reserved for patients who have not responded to other treatments. It is usually taken by mouth in pill or liquid form twice per day; an injectable form is also available. It is occasionally used to treat kidney disease due to lupus.",
"    </p>",
"    <p>",
"     Side effects include high blood pressure, swelling, kidney damage, increased hair growth, nausea, diarrhea, and heartburn. Patients should have blood pressure and kidney function monitoring on a regular basis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      BIOLOGIC AGENTS",
"     </span>",
"    </p>",
"    <p>",
"     Another class of medications used in persons with rheumatoid arthritis and related inflammatory rheumatic conditions is biologic agents, sometimes called biologic DMARDs, including etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab, which are all part of a class of drugs called tumor necrosis factor (TNF) inhibitors, and a variety of other agents with different targets, including anakinra, abatacept , rituximab, and tocilizumab. These medications are often combined with methotrexate or other DMARDs to improve efficacy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link&amp;anchor=H14#H14\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\", section on 'Biologic agents'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287385531\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263300810\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/61/12242?source=see_link\">",
"      Patient information: Juvenile rheumatoid arthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=see_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/21/27986?source=see_link\">",
"      Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=see_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263300802\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33382?source=see_link\">",
"      Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=see_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/hi/index.htm\">",
"        www.niams.nih.gov/hi/index.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"       <br/>",
"       phone: 404-633-3777",
"       <br/>",
"       fax: 404-633-1870",
"      </li>",
"      <li>",
"       American Academy of Family Physicians",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aafp.org/\">",
"        www.aafp.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?26/40/27266/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?26/40/27266?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27266/abstract/1\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27266/abstract/2\">",
"      O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27266/abstract/3\">",
"      Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 1999; 26:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27266/abstract/4\">",
"      Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract 2003; 57:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27266/abstract/5\">",
"      Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27266/abstract/6\">",
"      Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006; 8:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f26_40_27266=[""].join("\n");
var outline_f26_40_27266=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DISEASE-MODIFYING ANTIRHEUMATIC DRUG OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT ARE DISEASE-MODIFYING ANTIRHEUMATIC DRUGS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DISEASE-MODIFYING ANTIRHEUMATIC DRUGS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           BIOLOGIC AGENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f26_40_27267="Outer thigh stretch PI";
var content_f26_40_27267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Outer thigh stretches",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand at arm's length away from a wall with the right leg nearest to the wall. Cross the right leg behind the left leg. Carrying all the weight on the left leg, bend the elbow and lean into the wall. Hold for 5 seconds. A stretch should be felt through the hip and side of the body. Stand up straight and rest. Repeat 10 times then switch sides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27267=[""].join("\n");
var outline_f26_40_27267=null;
var title_f26_40_27268="Pelvic ring fracture classification";
var content_f26_40_27268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Young and Burgess classification for pelvic ring fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The red arrows illustrate the force direction. A) Lateral compression injuries with subsequent bilateral involvement as forces increase; B) Anteroposterior injuries with progression of injury; C) Vertical shear injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Burgess AR, Eastridge BJ, Young JW, et al. Pelvic ring disruptions: effective classification system and treatment protocols. J Trauma 1990; 30:848. Copyright &copy; 1990 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27268=[""].join("\n");
var outline_f26_40_27268=null;
var title_f26_40_27269="Tardive dyskinesia: Clinical features and diagnosis";
var content_f26_40_27269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tardive dyskinesia: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/40/27269/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27269/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/40/27269/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27269/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/40/27269/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27269/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/40/27269/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tardive dyskinesia (TD) is a hyperkinetic movement disorder that appears with a delayed onset after prolonged use of dopamine receptor blocking agents, mainly the antipsychotic drugs (also called neuroleptics) and the antiemetic drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    TD has numerous clinical manifestations that include chorea, athetosis, dystonia, akathisia, stereotyped behaviors, and rarely tremor. The term \"tardive\" differentiates these dyskinesia from acute dyskinesia, parkinsonism, and akathisia, which appear very soon after exposure to antipsychotic drugs.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of TD will be reviewed here. Other aspects of TD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=see_link\">",
"     \"Tardive dyskinesia: Prevention and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of tardive dyskinesia (TD) can include a variable mixture of orofacial dyskinesia, athetosis, dystonia, chorea, tics, and facial grimacing. The symptoms involve the mouth, tongue, face, trunk, or extremities. Tardive tremor has been rarely described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral, facial, and lingual dyskinesia are especially conspicuous in elderly patients. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protruding and twisting movements of the tongue",
"     </li>",
"     <li>",
"      Pouting, puckering, or smacking movements of the lips",
"     </li>",
"     <li>",
"      Retraction of the corners of the mouth",
"     </li>",
"     <li>",
"      Bulging of the cheeks",
"     </li>",
"     <li>",
"      Chewing movements",
"     </li>",
"     <li>",
"      Blepharospasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tongue movements are insidious in onset and at first may be limited to subtle back and forth or lateral movements. In other patients, tic-like facial movements or increased blink frequency are initial manifestations.",
"   </p>",
"   <p>",
"    Dyskinesia of the limbs also occur, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Twisting, spreading, and \"piano-playing\" finger movements",
"     </li>",
"     <li>",
"      Tapping foot movements",
"     </li>",
"     <li>",
"      Dystonic extensor postures of the toes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limb involvement is often more severe in younger individuals in whom dystonic postures and ballistic movements may occur.",
"   </p>",
"   <p>",
"    Dyskinesia of the neck and trunk may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retrocollis",
"     </li>",
"     <li>",
"      Torticollis",
"     </li>",
"     <li>",
"      Axial dystonia",
"     </li>",
"     <li>",
"      Shoulder shrugging",
"     </li>",
"     <li>",
"      Rocking and swaying movements",
"     </li>",
"     <li>",
"      Rotatory or thrusting hip movements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Respiratory dyskinesia may produce tachypnea, irregular breathing rhythms, and grunting noises that are commonly misinterpreted as primary respiratory problems.",
"   </p>",
"   <p>",
"    Severe orofacial dyskinesia is highly disfiguring and may greatly interfere with speech, eating, swallowing, or breathing, while truncal dystonia can be extremely distressing and interfere with gait and mobility.",
"   </p>",
"   <p>",
"    TD is much less common in children than in adults. The manifestations of TD in children have been called \"withdrawal emergent symptoms\" because they usually occur when antipsychotic drugs are discontinued.",
"   </p>",
"   <p>",
"    Cognitively intact and psychiatrically stable patients are usually very aware of mild and early manifestations of TD. In contrast, failure to complain of TD symptoms often occurs in patients with little insight who are chronically institutionalized or psychotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Subtypes of tardive dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of TD variants or subtypes have been described based on the type of involuntary movements that predominate in these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tardive dystonia refers to TD in which more sustained dystonic manifestations such as retrocollis, opisthotonus, shoulder dystonia, hyperextension of the arms or legs, blepharospasm, and jaw dystonia predominate [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/5\">",
"       5",
"      </a>",
"      ]. Tardive dystonia occurs more frequently in patients younger than age 40; it may have a lower spontaneous remission rate than TD.",
"     </li>",
"     <li>",
"      Tardive akathisia refers to late-appearing motor restlessness. It differs from acute akathisia by the presence of dyskinesia and absence of subjective motor restlessness [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tardive tics, tardive myoclonus, tardive stereotypy, tardive tremor, and tardive oral pain syndromes have also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/3\">",
"       3",
"      </a>",
"      ], but these are rare and often difficult to distinguish from other manifestations of TD or from effects of the patient's underlying psychosis. Many of these additional manifestations were well described in early reports of TD. They typically coexist with the more common manifestations. They illustrate the notion that TD encompasses a variety of motor manifestations without delineating a specific movement disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TD has also been classified based upon symptom duration or chronologic appearance and remission. In this scheme, subtypes include transient TD, withdrawal emergent TD, and persistent TD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient TD is limited to a relatively brief period of time during the course of treatment with antipsychotic drugs followed by spontaneous resolution",
"     </li>",
"     <li>",
"      Withdrawal emergent TD has been used to describe dyskinesia in pediatric patients that occurs transiently, immediately following the discontinuation of antipsychotic drugs",
"     </li>",
"     <li>",
"      Persistent TD refers to long-lasting or permanent TD",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of TD is insidious and typically occurs while the patient is receiving an antipsychotic drug. TD may appear as early as one to six months following antipsychotic drug exposure. In the initial literature, it was believed that TD occurred only after two or more years of antipsychotic treatment.",
"   </p>",
"   <p>",
"    It is common for TD to first appear after a reduction in dose, after switching to a less potent antipsychotic drug, or following discontinuation of an antipsychotic drug. This \"unmasking\" effect is due to the hypokinetic effects of antipsychotic drugs that frequently cause a delay in the recognition of TD. Withdrawal dyskinesia usually resolves within several weeks of antipsychotic drug discontinuation, but is likely to be a precursor of more persistent forms of TD.",
"   </p>",
"   <p>",
"    Although once considered a persistent or permanent condition, TD is often reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/9\">",
"     9",
"    </a>",
"    ]. In initial studies, remission rates of persistent TD were only 5 to 40 percent, but early identification of TD in younger outpatient populations is associated with remission in 50 to 90 percent of patients. Remission of TD usually occurs within several months after antipsychotic drug withdrawal, but may occur as late as one to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of TD in patients who require continued antipsychotic drug treatment is unknown. In most cases, TD either remains unchanged, or is suppressed by the hypokinetic effects of the antipsychotic drug when used at a higher dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of TD is based upon the presence of dyskinetic or dystonic involuntary movements, a history of at least one month of antipsychotic drug treatment, and the exclusion of other causes of abnormal movements.",
"   </p>",
"   <p>",
"    It is important to identify TD as early as possible since, as noted in the preceding section, the potential for remission appears to be related to the duration of symptoms before discontinuation of the antipsychotic drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of TD is usually straightforward, clinicians should consider other important causes of involuntary movements, such as Wilson disease or Huntington disease, in patients being treated with antipsychotic drugs for a psychiatric disorder. A comprehensive, methodical drug history is an essential part of the diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=see_link\">",
"     \"Huntington disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advanced Huntington disease is readily identified clinically by the positive family history, marked gait abnormality, and dementia. Early-stage Huntington disease can be harder to differentiate from TD because involuntary choreiform movements may be the only manifestation, and may be mild.",
"   </p>",
"   <p>",
"    TD must be distinguished from the stereotypies and psychotic mannerisms associated with chronic schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/13\">",
"     13",
"    </a>",
"    ], autism, and severe mental retardation. Stereotypies in schizophrenia are usually less rhythmic, more stereotyped, and more complex in appearance than the simpler, repetitive, and often rhythmic involuntary movements associated with TD. Unlike TD, choreoathetosis and dystonia are absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Motor mannerisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TD should also be distinguished from other antipsychotic drug-induced extrapyramidal syndromes that often coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233794#H272233794\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524651#H76524651\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Akathisia occurs both early and late in antipsychotic drug treatment and, in the case of tardive akathisia, may persist after cessation of such treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/6\">",
"       6",
"      </a>",
"      ]. Akathisia is a subjective feeling of motor restlessness accompanied by inability to sit or stand still. Manifestations may include repeated leg crossing, weight shifting, or stepping in place. When akathisic movements of the legs occur late in antipsychotic drug treatment and are associated with dyskinesia elsewhere in the body, they are referred to as tardive akathisia and should be considered a manifestation of TD.",
"     </li>",
"     <li>",
"      Acute dyskinesia typically occurs immediately after introduction of an antipsychotic drug, but may resemble TD. Acute dyskinesia can sometimes occur late in treatment after switching to a more potent antipsychotic drug, or can occur episodically during treatment with long-acting injectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      esters.",
"     </li>",
"     <li>",
"      With rare exception [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/1,2\">",
"       1,2",
"      </a>",
"      ], tremor is an uncommon manifestation of TD. Tremor is nearly always a reversible sign, usually associated with rigidity and akinesia, due to drug-induced parkinsonism. Rabbit syndrome is a rare perioral tremor that also may occur late in antipsychotic treatment, but, like other tremors, remits with discontinuation of antipsychotic drugs.",
"     </li>",
"     <li>",
"      Spontaneous orofacial dyskinesia often occurs in elderly people. The mean prevalence of dyskinesia among patients treated with antipsychotic drugs has been estimated at 20 percent, compared with a mean prevalence of 5 percent in untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/40/27269/abstract/14\">",
"       14",
"      </a>",
"      ]. This indicates that a significant background level of spontaneous dyskinesia is present in the general population, especially in the elderly. Spontaneous oral dyskinesia in the elderly is often associated with edentulism and dementia.",
"     </li>",
"     <li>",
"      Meige syndrome is an idiopathic cranial dystonia with onset in middle age manifested by blepharospasm and oromandibular dystonia. Meige syndrome, blepharospasm, and oromandibular dystonia are all phenotypically indistinguishable from orofacial TD. Thus, differentiating these conditions from TD depends on an adequate drug history.",
"     </li>",
"     <li>",
"      In a young person, tardive dystonia involving axial or cervical muscles should be differentiated from primary torsion dystonia, which has a slowly progressive course and is not related to antipsychotic drug exposure.",
"     </li>",
"     <li>",
"      Tourette syndrome is easily identified by a history of fluctuating motor and vocal tics since childhood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link\">",
"       \"Tourette syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other, less common possibilities in the differential diagnosis of TD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Facial grimacing and choreoathetosis associated with chronic liver disease",
"     </li>",
"     <li>",
"      Chorea or dystonia with antiphospholipid antibody syndrome",
"     </li>",
"     <li>",
"      Chorea due to hyperthyroidism or hypoparathyroidism",
"     </li>",
"     <li>",
"      Rheumatic or lupus chorea",
"     </li>",
"     <li>",
"      Acute drug intoxications with levodopa, amphetamines, anticholinergic drugs, certain calcium channel blockers with dopamine receptor blocking effects (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"       flunarizine",
"      </a>",
"      and cinnarizine, which are unavailable in the United States), antidepressants, and anticonvulsants",
"     </li>",
"     <li>",
"      Basal ganglia calcification and structural disorders of the basal ganglia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/10/1186?source=see_link\">",
"       \"Patient information: Tardive dyskinesia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manifestations of tardive dyskinesia (TD) can include a variable mixture of orofacial dyskinesia, athetosis, dystonia, chorea, tics, and facial grimacing. The symptoms involve the mouth, tongue, face, trunk, or extremities. Tardive tremor has also been rarely described. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of TD variants or subtypes have been described based on the type of involuntary movements that predominate in these conditions, including the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tardive dystonia",
"     </li>",
"     <li>",
"      Tardive akathisia",
"     </li>",
"     <li>",
"      Tardive tics",
"     </li>",
"     <li>",
"      Tardive myoclonus",
"     </li>",
"     <li>",
"      Tardive stereotypy",
"     </li>",
"     <li>",
"      Tardive tremor",
"     </li>",
"     <li>",
"      Tardive oral pain syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Subtypes of tardive dyskinesia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of TD is insidious and typically occurs while the patient is receiving an antipsychotic drug. In addition, it is common for TD to first appear after a reduction in dose, after switching to a less potent antipsychotic drug, or following discontinuation of an antipsychotic drug. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although once considered a persistent or permanent condition, TD is often reversible. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TD is based on the presence of dyskinetic or dystonic involuntary movements, a history of at least one month of antipsychotic drug treatment, and the exclusion of other causes of abnormal movements. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TD should be distinguished from other extrapyramidal syndromes, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Huntington disease",
"     </li>",
"     <li>",
"      Akathisia",
"     </li>",
"     <li>",
"      Acute dyskinesia",
"     </li>",
"     <li>",
"      Stereotypies associated with chronic schizophrenia, autism, and severe mental retardation",
"     </li>",
"     <li>",
"      Spontaneous orofacial dyskinesia",
"     </li>",
"     <li>",
"      Meige syndrome",
"     </li>",
"     <li>",
"      Blepharospasm",
"     </li>",
"     <li>",
"      Oromandibular dystonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/1\">",
"      Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/2\">",
"      Tarsy D, Indorf G. Tardive tremor due to metoclopramide. Mov Disord 2002; 17:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/3\">",
"      Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995; 18:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/4\">",
"      Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003; 9:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/5\">",
"      Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32:1335.",
"     </a>",
"    </li>",
"    <li>",
"     Tarsy, D. Akathisia. In: Movement Disorders in Neurology and Neuropsychiatry, Joseph, AB, Young, RR (Eds), Blackwell, Boston 1999. p.75.",
"    </li>",
"    <li>",
"     Tarsy, D, Baldessarini, RJ. The tardive dyskinesia syndrome. In: Clinical Neuropharmacology, Klawans, HL (Ed), Raven Press, New York 1976. p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/8\">",
"      Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/9\">",
"      Tarsy D. History and definition of tardive dyskinesia. Clin Neuropharmacol 1983; 6:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/10\">",
"      Tarsy D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med 1984; 35:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/11\">",
"      Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/12\">",
"      Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001; 56:805.",
"     </a>",
"    </li>",
"    <li>",
"     Marsden, CD, Tarsy, D, Baldessarini, RJ. Spontaneous and drug-induced movement disorders in psychotic patients. In: Psychiatric Aspects of Neurologic Disease, Benson, DF, Blumer, D (Eds), Grune and Stratton, New York 1975. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27269/abstract/14\">",
"      Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39:473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4909 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27269=[""].join("\n");
var outline_f26_40_27269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Subtypes of tardive dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/10/1186?source=related_link\">",
"      Patient information: Tardive dyskinesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=related_link\">",
"      Tardive dyskinesia: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_40_27270="de Quervain's tenosynovitis";
var content_f26_40_27270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   de Quervain's tenosynovitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Rohit Aggarwal, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/40/27270/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/40/27270/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;de Quervain&rsquo;s tenosynovitis refers to entrapment",
"    <span class=\"nowrap\">",
"     tendonitis/tenosynovitis",
"    </span>",
"    of the abductor pollicis longus and extensor pollicis brevis tendons at the styloid process of the radius. It is most often a cumulative movement disorder due to chronic overuse of the wrist and hand. Bilateral or unilateral tenosynovitis may also accompany pregnancy, direct trauma, and systemic diseases such as rheumatoid arthritis and calcium apatite deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and treatment of de Quervain&rsquo;s tenosynovitis are discussed here. An overview of overuse tendinopathies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=see_link\">",
"     \"Overview of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30139679\">",
"    <span class=\"h1\">",
"     ETIOPATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;de Quervain&rsquo;s tenosynovitis affects two thumb tendons: the abductor pollicis longus (APL) and the extensor pollicis brevis (EPB). These tendons are responsible for extending the thumb backwards and for moving the thumb away from the palm of the hand. These tendons connect their respective muscles in the forearm to the thumb. On their way to the thumb, the APL and EPB traverse side-by-side through a thick fibrous sheath that forms a tunnel at the radial styloid process [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Normally, the APL and EPB glide easily back and forth within this tunnel.",
"   </p>",
"   <p>",
"    Repetitive or unaccustomed use of the thumb that involves pinching with the thumb while moving the wrist in radial and ulnar directions (eg, gripping and grasping) leads to thickening of the fibrous tendon sheath. Thickening results in inflammation and stenosis as the tendon sheath passes over the distal radius. Left untreated, this friction-induced tenosynovitis can progress to fibrosis and loss of flexibility of the thumb in flexion (stenosing tenosynovitis). Histologically, at this stage, there is a lack of inflammation, and there are widespread degenerative changes affecting the sheath and the tendon itself [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=see_link&amp;anchor=H32168053#H32168053\">",
"     \"Overview of overuse (chronic) tendinopathy\", section on 'Pathology and terminology: tendinosis versus tendinitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37508?source=see_link\">",
"     \"Joint protection program for the upper limb\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct trauma to the first extensor (dorsal) compartment in the region of the radial styloid can also lead to inflammation in this region, subsequently leading to de Quervain&rsquo;s tenosynovitis. In addition, systemic diseases like rheumatoid arthritis or calcium apatite deposition disease may lead to synovitis of the wrist, which may sometimes lead to de Quervain&rsquo;s tenosynovitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;de Quervain&rsquo;s tenosynovitis is the most common entrapment tendonitis of hand and wrist after trigger finger. It is most commonly seen in women between 30 and 50 years of age. Patients with de Quervain&rsquo;s tenosynovitis typically note pain at the radial side of the wrist during pinch grasping or during thumb and wrist movement. Pain may radiate to the thumb or up to the volar aspect of the wrist. The patient may complain of difficulty gripping and often rubs over the radial styloid when describing the condition. The patient may present with painful swelling or enlargement of the first extensor (dorsal) compartment. Patients often have tenderness and thickening at the radial styloid. Crepitation as seen in carpal-metacarpal (CMC) joint osteoarthritis is absent.",
"   </p>",
"   <p>",
"    Mothers caring for infants aged 6 to 12 months may be affected, and symptoms are often noted in both wrists. Daycare workers and other persons who repetitively lift infants are frequently affected as well. de Quervain&rsquo;s tenosynovitis can also develop after direct trauma to the area of the first extensor (dorsal) compartment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of de Quervain&rsquo;s tenosynovitis is suggested by the characteristic history of wrist pain on the radial side and by the following physical examination findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask the patient to open and close the hand to assess the full and smooth movement of the thumb. Smooth, painless, and complete movement of the thumb virtually excludes de Quervain&rsquo;s tenosynovitis.",
"     </li>",
"     <li>",
"      Local tenderness is present over the distal portion of the radial styloid, adjacent to the abductor pollicis longus tendon (",
"      <a class=\"graphic graphic_picture graphicRef67845 \" href=\"UTD.htm?21/28/21967\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pain is aggravated by resisting thumb extension and abduction isometrically (abduction is moving the thumb perpendicular to the palm) (",
"      <a class=\"graphic graphic_picture graphicRef56635 \" href=\"UTD.htm?26/54/27503\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pain is aggravated by passively stretching the thumb tendons over the radial styloid in thumb flexion (the Finkelstein maneuver or test) (",
"      <a class=\"graphic graphic_picture graphicRef58422 \" href=\"UTD.htm?22/14/22752\">",
"       picture 3",
"      </a>",
"      ). This motion stretches the tendon and tendon sheath and, in some cases, is so painful that the patient responds by lifting the shoulder to prevent the examiner from stretching the tendons.",
"     </li>",
"     <li>",
"      Palpation of the tendons in the anatomic &ldquo;snuff box&rdquo; area may reveal swelling (thickening) or tenderness when compared with the uninvolved side.",
"     </li>",
"     <li>",
"      Tendon fibrosis is assessed by evaluating flexion and circumduction of the thumb and by assessing the distensibility of the tissues over the radial styloid. Normally, the soft tissues of the radial styloid should readily distend with 2 to 3 mL of local anesthetic, forming a bubble 1.5 inches long.",
"     </li>",
"     <li>",
"      Tenderness and pain upon axial loading at the carpometacarpal (CMC) joint and crepitation of the CMC joint do not occur due to de Quervain&rsquo;s tenosynovitis, thus helping to differentiate it from CMC osteoarthritis, which may also cause pain at the radial aspect of the wrist. Occasionally, both entities, as well as related symptoms and physical findings, may be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of trauma to the distal radius, radial styloid tenderness coupled with pain aggravated by resisting thumb extension is highly suggestive of active tenosynovitis. A positive Finkelstein test provides further confirmation of the diagnosis, although the test also can be positive in patients with carpometacarpal (CMC) osteoarthritis of the thumb [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/7\">",
"     7",
"    </a>",
"    ]. (See below.) Local anesthetic block directly over the radial styloid is often necessary to differentiate de Quervain&rsquo;s tenosynovitis from an arthritic flare of the CMC joint and can be performed by primary care clinicians (",
"    <a class=\"graphic graphic_picture graphicRef65518 \" href=\"UTD.htm?23/34/24111\">",
"     picture 4",
"    </a>",
"    ); effective relief of symptoms with injection excludes an arthritic etiology.",
"   </p>",
"   <p>",
"    X-rays of the wrist and thumb are not usually necessary in most patients. Plain films of these areas are normal in patients with de Quervain&rsquo;s tenosynovitis; calcification of the affected tendons does not occur. However, x-rays may be helpful in identifying CMC osteoarthritis as a potential cause of local pain, although the two conditions can often coexist. In patients suspected of a distal radial bone tumor or of an occult scaphoid fracture, a radiograph may also be of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of de Quervain&rsquo;s tenosynovitis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Osteoarthritis of the first carpometacarpal joint",
"     </li>",
"     <li>",
"      Tendinitis of the wrist extensors",
"     </li>",
"     <li>",
"      Ganglia",
"     </li>",
"     <li>",
"      Radial sensory nerve entrapment in the forearm",
"     </li>",
"     <li>",
"      Infectious or noninfectious tenosynovitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Osteoarthritis of the first CMC joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis of the first carpometacarpal (CMC) joint may cause pain near the radial styloid and can coexist with tenosynovitis. As mentioned, the Finkelstein test may be positive in either of these disorders, requiring local anesthetic injection to differentiate between them. It is also helpful to perform crank (axial load on thumb and",
"    <span class=\"nowrap\">",
"     flexion/extension)",
"    </span>",
"    and grind (axial load on thumb and metacarpal rotation) tests to rule out CMC joint osteoarthritis. In some patients, CMC osteoarthritis itself might be the cause of recurrent de Quervain&rsquo;s tenosynovitis, and both will require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tendinitis of the wrist extensors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendinitis of the wrist extensors may present with pain during active movement of the wrist and with local tenderness. It is often detected by the presence of crepitation during palpation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ganglia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist is a common site for ganglia, which are cystic swellings arising from a joint capsule or tendon sheath. Ganglia can cause wrist pain but can be distinguished from tenosynovitis by palpation of a mass on physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41223?source=see_link\">",
"     \"Ganglia and nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radial sensory nerve entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial sensory nerve entrapment in the forearm causes burning pain, paresthesias over the dorsum of the hand, and a positive Tinel sign over the nerve in the mid-forearm just distal to the brachioradialis muscle belly. Forearm hyperpronation will often reproduce the symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/8\">",
"     8",
"    </a>",
"    ]. Tight jewelry may be the cause in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infectious tenosynovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious tenosynovitis is an uncommon disorder that is often the result of puncture wounds or lacerations. It is imperative to recognize this syndrome since the closed space infection can lead to severe limitation of motion due tendon disruption. Clinical findings include",
"    <strong>",
"     severe pain",
"    </strong>",
"    and tenderness over the involved tendon sheath, pain on passive extension of the finger, flexed attitude of the finger, fusiform swelling of the involved digit, and regional lymphadenopathy.",
"   </p>",
"   <p>",
"    Tuberculous tenosynovitis should be an immediate consideration if massive swelling of a single flexor tendon from the palm all the way out to the distal finger is noted (",
"    <a class=\"graphic graphic_picture graphicRef71084 \" href=\"UTD.htm?12/30/12782\">",
"     picture 5",
"    </a>",
"    ). The absence of warmth and pain are additional features. Tuberculous tenosynovitis may also present as a &ldquo;compound palmar ganglion&rdquo; in which gradually enlarging rubbery masses are noted; these are slightly tender but are without warmth or redness. Destruction of the enclosed tendons may occur, and hematogenous spread is the rule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2986260\">",
"    <span class=\"h2\">",
"     Noninfectious tenosynovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious tenosynovitis of the wrist and hand can be caused by inflammatory arthritic conditions, such as rheumatoid arthritis and calcium pyrophosphate deposition diseases like pseudogout (acute calcium pyrophosphate crystal arthritis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment of de Quervain&rsquo;s tenosynovitis are to reduce inflammation in the tenosynovial sac, to prevent the formation of adhesions, and to prevent recurrent tendinitis (with exercises and altering lifting and grasping).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy in the acute setting consists of pain relief and restriction of thumb gripping and grasping. Although splinting of the thumb and wrist helps, the loss of thumb range of motion for functional activities may lead to poor compliance with the splint.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain relief can be accomplished with ice applications to the radial styloid (for 15 minutes every four to six hours). Nonsteroidal antiinflammatory may also be helpful if symptoms are of recent onset and are not severe. Phonophoresis (application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      gel to the radial styloid area daily) helps relieve pain in minor cases.",
"     </li>",
"     <li>",
"      Thumb movement should be restricted by buddy taping the base of the thumb to the first finger, a Velcro thumb spica splint, or a dorsal hood splint. The first two do not extend distally from the wrist, which is potentially a disadvantage, and the splint may need to be extended if the patient does not respond initially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gentle passive stretching exercises of the extensor and abductor tendons should begin once the signs and symptoms of active tenosynovitis have resolved (usually three to four weeks). Sets of 20 stretches, each held for five seconds, should be performed daily. This can be accomplished by teaching the patient to perform the Finkelstein maneuver (",
"    <a class=\"graphic graphic_picture graphicRef58422 \" href=\"UTD.htm?22/14/22752\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When de Quervain&rsquo;s tenosynovitis occurs during pregnancy, it frequently responds well to conservative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients may have spontaneous resolution of symptoms either at the end of pregnancy or at the end of breast feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A local intralesional glucocorticoid injection into the sheath of the first extensor (dorsal) compartment is indicated if pain or swelling is persistent for two to six weeks despite the above measures (",
"    <a class=\"graphic graphic_picture graphicRef65518 \" href=\"UTD.htm?23/34/24111\">",
"     picture 4",
"    </a>",
"    ). The injection may be repeated at four to six weeks if symptoms are not reduced by 50 percent.",
"   </p>",
"   <p>",
"    Up to 90 percent of patients treated within six months of developing symptoms have relief of pain following glucocorticoid injection. Complications are rare, and most can resume normal activities within three weeks (often within the first week) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. Approximately 50 to 60 percent of patients have complete resolution of symptoms with a single injection, 30 to 40 percent have complete resolution after a second injection, and 10 percent fail to respond and require surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who have had symptoms for longer than six months prior to treatment are at risk for fibrosis (stenosing tenosynovitis). Local injection combined with dilation of the soft tissues over the radial styloid can be used in these individuals, but the success rate is lower.",
"   </p>",
"   <p>",
"    Severe cases that require a second injection can be treated concurrently with a dorsal hood splint (",
"    <a class=\"graphic graphic_picture graphicRef62305 \" href=\"UTD.htm?12/13/12496\">",
"     picture 6",
"    </a>",
"    ) or with a short-arm cast with a thumb spica (",
"    <a class=\"graphic graphic_picture graphicRef81987 \" href=\"UTD.htm?30/55/31615\">",
"     picture 7",
"    </a>",
"    ). The former can be placed by an occupational therapist. The wrist is immobilized in slight extension and radial deviation, while maintaining slight extension of the first metacarpophalangeal (MCP) joint. Splinting may be required for several weeks or until tenderness and pain on motion subside. Passive thumb stretching should continue also during this time. Patients receiving an injection and splinting are more likely to respond than are those who are only splinted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate aftercare is critical to the success of glucocorticoid injection. Patients should be advised as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rest the thumb for three days.",
"     </li>",
"     <li>",
"      Ice the area for 15 minutes every four to six hours and take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (1000 mg twice daily) for pain.",
"     </li>",
"     <li>",
"      Protect the wrist for three to four weeks with a splint (this is optional).",
"     </li>",
"     <li>",
"      Avoid grasping and lifting with the wrist ulnar deviated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, glucocorticoid injection is very well-tolerated. It is important to inject the medication into the sheath of the first extensor (dorsal) compartment and not subcutaneously. Adverse effects of subcutaneous injection of glucocorticoids in this region include fat and dermal atrophy, which may take up to six months to resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Referral and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical consultation is indicated if symptoms are recurrent or persist after two injections within one year. Surgery involves decompression of the first extensor (dorsal) compartment with or without tenosynovectomy. The success rate of surgery is better than 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/40/27270/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Surgery is a simple outpatient surgical procedure which can be performed using local or regional anesthesia.",
"   </p>",
"   <p>",
"    Potential complications of surgery include injury of the superficial radial sensory nerve, continued symptoms from an incomplete release, and the formation of radial sensory neuromas from unrepaired lacerations of the nerve. In addition, the abductor pollicis brevis and the extensor pollicis brevis tendons can potentially prolapse volarly. A common anatomical variant of multiple tendons of the abductor pollicis longus can lead to incomplete release if not identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/58/36769?source=see_link\">",
"       \"Patient information: De Quervain&rsquo;s tenosynovitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=see_link\">",
"       \"Patient information: Tenosynovitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660498\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      de Quervain&rsquo;s tenosynovitis refers to entrapment",
"      <span class=\"nowrap\">",
"       tendonitis/tenosynovitis",
"      </span>",
"      of the abductor pollicis longus and extensor pollicis brevis tendons where they traverse side-by-side through a thick fibrous sheath that forms a tunnel at the radial styloid process. It is most often a cumulative movement disorder due repetitive or unaccustomed use of the thumb that involves pinching with the thumb while moving the wrist in radial and ulnar directions (eg, gripping and grasping). Bilateral or unilateral tenosynovitis may also accompany pregnancy, direct trauma, and systemic inflammatory joint diseases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30139679\">",
"       'Etiopathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with de Quervain&rsquo;s tenosynovitis typically note pain at the radial side of the wrist during pinch grasping or during thumb and wrist movement. Pain may radiate to the thumb or up to the volar aspect of the wrist. There may be painful swelling or enlargement of the first extensor (dorsal) compartment, and patients often have tenderness and thickening at the radial styloid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radial styloid tenderness coupled with pain aggravated by resisting thumb extension (",
"      <a class=\"graphic graphic_picture graphicRef56635 \" href=\"UTD.htm?26/54/27503\">",
"       picture 2",
"      </a>",
"      ) is highly suggestive of active tenosynovitis, in the absence of trauma to the distal radius. A positive Finkelstein test provides further confirmation of the diagnosis (",
"      <a class=\"graphic graphic_picture graphicRef58422 \" href=\"UTD.htm?22/14/22752\">",
"       picture 3",
"      </a>",
"      ), although the test also can be positive in patients with carpometacarpal (CMC) osteoarthritis of the thumb. Smooth, painless, and complete movement of the thumb while actively opening and closing the hand virtually excludes de Quervain&rsquo;s tenosynovitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of de Quervain&rsquo;s tenosynovitis includes osteoarthritis of the first carpometacarpal joint, which may also cause a positive Finkelstein test, requiring local anesthetic injection to differentiate between them. Tenderness and pain upon axial loading at the CMC joint and crepitation of the CMC joint do not occur due to de Quervain&rsquo;s tenosynovitis, thus helping to differentiate it from CMC osteoarthritis, but both conditions may occur together. Other considerations in the differential diagnosis are tendinitis of the wrist extensors, ganglia, radial sensory nerve entrapment in the forearm, and infectious or noninfectious tenosynovitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment of de Quervain&rsquo;s tenosynovitis are to reduce inflammation in the tenosynovial sac, to prevent the formation of adhesions, and to prevent recurrent tendinitis. Therapy in the acute setting consists of pain relief and restriction of thumb gripping and grasping. Although splinting of the thumb and wrist helps, the loss of thumb range of motion for functional activities may lead to poor compliance with the splint. Icing, nonsteroidal antiinflammatories, and splinting are helpful, and stretching exercises of the extensor and abductor tendons should begin once the signs and symptoms of active tenosynovitis have resolved. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Acute therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A local intralesional glucocorticoid injection into the sheath of the first extensor (dorsal) compartment is indicated if pain or swelling is persistent for two to six weeks despite initial measures. Most patients treated within six months of developing symptoms respond with substantial relief of pain after one or two injections. Patients require rest of the thumb for several days postinjection, along with icing and avoidance of aggravating activities; splinting may also be of benefit. Many patients can resume normal activities within three weeks of injection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Persistent symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical consultation is indicated if symptoms are recurrent or persist after two injections within one year. Surgery involves decompression of the first extensor (dorsal) compartment with or without tenosynovectomy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Referral and surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20817873\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert P Sheon, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/1\">",
"      Schumacher HR Jr, Dorwart BB, Korzeniowski OM. Occurrence of De Quervain's tendinitis during pregnancy. Arch Intern Med 1985; 145:2083.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 2nd, WB Saunders, Philadelphia 1999.",
"    </li>",
"    <li>",
"     Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd, Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/4\">",
"      de Quervain F. Uber eine Form von chronischer Tendovaginitis. Correspondenz-Blatt fur Schweizer Arzte 1895; 25:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/5\">",
"      Minamikawa Y, Peimer CA, Cox WL, Sherwin FS. De Quervain's syndrome: surgical and anatomical studies of the fibroosseous canal. Orthopedics 1991; 14:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/6\">",
"      Clarke MT, Lyall HA, Grant JW, Matthewson MH. The histopathology of de Quervain's disease. J Hand Surg Br 1998; 23:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/7\">",
"      Pick RY. De Quervain's disease: a clinical triad. Clin Orthop Relat Res 1979; :165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/8\">",
"      Saplys R, Mackinnon SE, Dellon AL. The relationship between nerve entrapment versus neuroma complications and the misdiagnosis of de Quervain's disease. Contemp Orthop 1987; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/9\">",
"      Avci S, Yilmaz C, Sayli U. Comparison of nonsurgical treatment measures for de Quervain's disease of pregnancy and lactation. J Hand Surg Am 2002; 27:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/10\">",
"      Capasso G, Testa V, Maffulli N, et al. Surgical release of de Quervain's stenosing tenosynovitis postpartum: can it wait? Int Orthop 2002; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/11\">",
"      Carlson CS Jr, Curtis RM. Steroid injection for flexor tenosynovitis. J Hand Surg Am 1984; 9:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/12\">",
"      Otto N, Wehb&eacute; MA. Steroid injections for tenosynovitis in the hand. Orthop Rev 1986; 15:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/13\">",
"      Anderson BC, Manthey R, Brouns MC. Treatment of De Quervain's tenosynovitis with corticosteroids. A prospective study of the response to local injection. Arthritis Rheum 1991; 34:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/14\">",
"      Witt J, Pess G, Gelberman RH. Treatment of de Quervain tenosynovitis. A prospective study of the results of injection of steroids and immobilization in a splint. J Bone Joint Surg Am 1991; 73:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/15\">",
"      Sakai N. Selective corticosteroid injection into the extensor pollicis brevis tenosynovium for de Quervain's disease. Orthopedics 2002; 25:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/16\">",
"      Richie CA 3rd, Briner WW Jr. Corticosteroid injection for treatment of de Quervain's tenosynovitis: a pooled quantitative literature evaluation. J Am Board Fam Pract 2003; 16:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/17\">",
"      Mehdinasab SA, Alemohammad SA. Methylprednisolone acetate injection plus casting versus casting alone for the treatment of de Quervain's tenosynovitis. Arch Iran Med 2010; 13:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/18\">",
"      Mellor SJ, Ferris BD. Complications of a simple procedure: de Quervain's disease revisited. Int J Clin Pract 2000; 54:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/40/27270/abstract/19\">",
"      Ta KT, Eidelman D, Thomson JG. Patient satisfaction and outcomes of surgery for de Quervain's tenosynovitis. J Hand Surg Am 1999; 24:1071.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7752 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-220.255.2.121-1001A7F1F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27270=[""].join("\n");
var outline_f26_40_27270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H660498\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30139679\">",
"      ETIOPATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Osteoarthritis of the first CMC joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tendinitis of the wrist extensors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ganglia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radial sensory nerve entrapment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infectious tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2986260\">",
"      Noninfectious tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Referral and surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660498\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20817873\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7752|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/28/21967\" title=\"picture 1\">",
"      Palpation radial styloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/54/27503\" title=\"picture 2\">",
"      Resisting thumb extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/14/22752\" title=\"picture 3\">",
"      Finkelstein test deQuervains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/34/24111\" title=\"picture 4\">",
"      de Quervains injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/30/12782\" title=\"picture 5\">",
"      Tuberculous tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/13/12496\" title=\"picture 6\">",
"      Dorsal hood splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/55/31615\" title=\"picture 7\">",
"      Thumb spica splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37508?source=related_link\">",
"      Joint protection program for the upper limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=related_link\">",
"      Overview of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/58/36769?source=related_link\">",
"      Patient information: De Quervain&rsquo;s tenosynovitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=related_link\">",
"      Patient information: Tenosynovitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_40_27271="Cross section transected tube";
var content_f26_40_27271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cross-section of transected fallopian tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic cross-section of a fallopian tube demonstrating complete destruction of the endosalpinx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27271=[""].join("\n");
var outline_f26_40_27271=null;
var title_f26_40_27272="Ondansetron: Pediatric drug information";
var content_f26_40_27272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ondansetron: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"    see \"Ondansetron: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/24/24965?source=see_link\">",
"    see \"Ondansetron: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13246131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Premixed Ondansetron 32 mg I.V. Products to be Removed From Market",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is notifying healthcare providers that ondansetron hydrochloride (Zofran&reg;) 32 mg single premixed intravenous doses in a sodium chloride or dextrose solution will no longer be marketed because of the potential for QT prolongation, which can lead to torsade de pointes, a potentially fatal abnormal heart rhythm. The I.V. 32 mg dose has been removed from GlaxoSmithKline's ondansetron (Zofran&reg;) labeling. The FDA is working with the manufacturers of all ondansetron 32 mg, premixed single-dose injectable products to voluntarily recall them from the market. The FDA anticipates these products will be removed from the market through early 2013 and does not expect this recall to contribute to a drug shortage.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The approved labeling continues to recommend I.V. ondansetron for the prevention of chemotherapy induced nausea and vomiting at 0.15 mg/kg every 4 hours for 3 doses. No single I.V. dose should exceed 16 mg. Oral dosing labeling for ondansetron is unchanged.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm330772.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm330772.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      QT Prolongation with Ondansetron",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Previously, in September 2011, the U.S. Food and Drug Administration (FDA) notified healthcare professionals about an ongoing safety review of the risk of QT prolongation with ondansetron. At that time, the FDA required GlaxoSmithKline (manufacturer of Zofran&reg;) to conduct an in-depth study on the effects of ondansetron on the QT interval. Recent preliminary study results suggest that a single intravenous dose of ondansetron (Zofran&reg;) 32 mg may prolong the QT interval, which could predispose patients to development of torsade de pointes. Those most at risk include patients with congenital long QT syndrome, heart failure, bradyarrhythmias, electrolyte abnormalities (ie, hypokalemia, hypomagnesemia), and concomitant use of other QT-prolonging medications. GlaxoSmithKline has announced changes to ondansetron labeling to remove the 32 mg single intravenous dose. Updated labeling will also state that ondansetron 0.15 mg/kg can be administered to patients with chemotherapy-induced nausea and vomiting every 4 hours for 3 doses, but no single intravenous dose should exceed 16 mg. The labeling for oral ondansetron will not be changed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zofran&reg;;",
"     </li>",
"     <li>",
"      Zofran&reg; ODT;",
"     </li>",
"     <li>",
"      Zuplenz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ondansetron&reg;;",
"     </li>",
"     <li>",
"      CO Ondansetron;",
"     </li>",
"     <li>",
"      Dom-Ondansetron;",
"     </li>",
"     <li>",
"      JAMP-Ondansetron;",
"     </li>",
"     <li>",
"      Mint-Ondansetron;",
"     </li>",
"     <li>",
"      Mylan-Ondansetron;",
"     </li>",
"     <li>",
"      Ondansetron Injection;",
"     </li>",
"     <li>",
"      Ondansetron Injection USP;",
"     </li>",
"     <li>",
"      Ondansetron-Odan;",
"     </li>",
"     <li>",
"      Ondansetron-Omega;",
"     </li>",
"     <li>",
"      PHL-Ondansetron;",
"     </li>",
"     <li>",
"      PMS-Ondansetron;",
"     </li>",
"     <li>",
"      RAN&trade;-Ondansetron;",
"     </li>",
"     <li>",
"      ratio-Ondansetron;",
"     </li>",
"     <li>",
"      Sandoz-Ondansetron;",
"     </li>",
"     <li>",
"      Teva-Ondansetron;",
"     </li>",
"     <li>",
"      Zofran&reg;;",
"     </li>",
"     <li>",
"      Zofran&reg; ODT;",
"     </li>",
"     <li>",
"      ZYM-Ondansetron",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-HT",
"       <sub>",
"        3",
"       </sub>",
"       Receptor Antagonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"      see \"Ondansetron: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chemotherapy- or radiotherapy-induced nausea and vomiting; prevention:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Infants, Children, and Adolescents: 0.15 mg/kg/dose infused 30 minutes before the start of emetogenic chemotherapy, with subsequent doses administered 4 and 8 hours after the first dose for 3 doses total; others have used a once-daily single dose of 0.3 mg/kg or 0.45 mg/kg dependent upon emetogenic potential of chemotherapy (Holdsworth, 2006); maximum dose: 16 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be administered 30 minutes before chemotherapy or 1-2 hours prior to radiotherapy and repeated at 8-hour intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children &lt;4 years: Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Weight-based dosing: 0.15 mg/kg/dose 3 times daily (Holdsworth, 2006); maximum dose: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Body-surface area (BSA)-based dosing: Children 2-4 years (Carden, 1990; Pinkerton, 1990):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     &lt;0.3 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1 mg/dose 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     0.3-0.6 m",
"     <sup>",
"      2",
"     </sup>",
"     : 2 mg/dose 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     0.6-1 m",
"     <sup>",
"      2",
"     </sup>",
"     : 3 mg/dose 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     &gt;1 m",
"     <sup>",
"      2",
"     </sup>",
"     : 4 mg/dose 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 4-11 years: 4 mg/dose 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children and Adolescents &ge;12 years: 8 mg/dose 3 times daily or 24 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cyclic vomiting syndrome (CVS); treatment of acute attack",
"     </b>",
"     (Li, 2008): I.V.: Children &gt;2 years: 0.3-0.4 mg/kg/dose every 4-6 hours; maximum dose: 16 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Gastroenteritis, acute; treatment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Routine use of ondansetron is not recommended in most cases of acute gastroenteritis (AAP, 2004; CDC, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Infants and Children &ge;1 month: 0.15 or 0.3 mg/kg/dose once; maximum dose: 16 mg (DeCamp, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: Infants and Children 6 months to 10 years, &ge;8 kg (Freedman, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     8-15 kg: 2 mg/dose once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;15-30 kg: 4 mg/dose once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;30 kg: 8 mg/dose once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting; prevention:",
"     </b>",
"     I.V.: Administer immediately before induction of anesthesia, or postoperatively if the patient is symptomatic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children 1 month to 12 years and &le;40 kg: 0.1 mg/kg/dose; maximum dose: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;40 kg, Adolescents: 4 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chemotherapy-induced emesis, prevention:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 0.15 mg/kg/dose (maximum dose: 16 mg) over 15 minutes for 3 doses, beginning 30 minutes prior to chemotherapy, followed by subsequent doses 4 and 8 hours after the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Highly emetogenic agents/single-day therapy: 24 mg given as three 8 mg tablets 30 minutes prior to the start of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderately emetogenic agents: 8 mg beginning 30 minutes before chemotherapy; repeat dose 8 hours after initial dose, then 8 mg every 12 hours for 1-2 days after chemotherapy completed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV), prevention: Note:",
"     </b>",
"     The manufacturer recommends administration immediately before induction of anesthesia; however, this has been shown not to be as effective as administration at the end of surgery (Sun, 1997). Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.: 4 mg as a single dose ~30 minutes before the end of anesthesia or as treatment if vomiting occurs after surgery (Gan, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 16 mg given 1 hour prior to induction of anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Radiation-induced emesis, prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Total body irradiation: Oral: 8 mg 1-2 hours before each daily fraction of radiotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Single high-dose fraction radiotherapy to abdomen: Oral: 8 mg 1-2 hours before irradiation, then 8 mg every 8 hours after first dose for 1-2 days after completion of radiotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Daily fractionated radiotherapy to abdomen: Oral: 8 mg 1-2 hours before irradiation, then 8 mg 8 hours after first dose for each day of radiotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hyperemesis gravidum, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 8 mg administered over 15 minutes every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 8 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No adjustment is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: Severe liver disease (Child-Pugh C): Maximum daily dose: 8 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, soluble, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zuplenz&reg;: 4 mg (10s); 8 mg (10s) [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [preservative free]: 32 mg (50 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 32 mg (50 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS [preservative free]: 32 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (2 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 2 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 2 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 4 mg/5 mL (5 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 4 mg/5 mL (50 mL) [contains sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg; ODT: 4 mg, 8 mg [contains phenylalanine &lt;0.03 mg/tablet; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral soluble film",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (all dosage forms): May administer without regard to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally disintegrating tablet (Zofran&reg; ODT): Do open until needed; peel foil back; do not push through foil backing. Place tablet on tongue, it will disintegrate immediately; may also swallow with fluids as whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soluble film (Zuplenz&reg;): Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4-20 seconds). Swallow with or without liquid. If using more than one film, allow each film to dissolve completely before administering the next film.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     IVPB infusion: For prevention of chemotherapy-related emesis, dilute to a maximum concentration of 1 mg/mL and infuse over 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. push: May be administered I.V. undiluted over 2-5 minutes for prevention of PONV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Administer as undiluted injection; use only in adults",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F203763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, mannitol 10%, LR, NS; do not mix injection with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, amifostine, amikacin, azithromycin, aztreonam, bleomycin, carboplatin, carmustine, caspofungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, cisatracurium, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, dexmedetomidine, diphenhydramine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, droperidol, etoposide, etoposide phosphate, famotidine, fenoldopam, filgrastim, floxuridine, fluconazole, fludarabine, gallium nitrate, gemcitabine, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, imipenem/cilastatin, linezolid, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, mitomycin, mitoxantrone, morphine, oxaliplatin, paclitaxel, paclitaxel with ranitidine, pentostatin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, remifentanil, sodium acetate, streptozocin, telavancin, teniposide, thiotepa, ticarcillin/clavulanate, topotecan, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, allopurinol, aminophylline, amphotericin B, amphotericin B cholesteryl sulfate complex, ampicillin, ampicillin/sulbactam, amsacrine, cefepime, furosemide, ganciclovir, lorazepam, methylprednisolone sodium succinate, micafungin, pemetrexed, sargramostim, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cyclosporine, fluorouracil, fosaprepitant, meropenem, piperacillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, atropine, fentanyl, glycopyrrolate, meperidine, metoclopramide, midazolam, morphine, naloxone, neostigmine, propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, droperidol.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally disintegrating tablets, tablets: Store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F); protect tablets from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soluble film (Zuplenz&reg;):  Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); store pouches in cartons; keep film in individual pouch until ready for use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: Store 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; store upright.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premixed bag in D",
"     <sub>",
"      5",
"     </sub>",
"     W: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), excursions allowed from 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); may refrigerate; avoid freezing and excessive heat; protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vial: Store unopened vials at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F); protect from light; when diluted in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W manufacturer recommends stability for 48 hours at room temperature and others have reported for 7 days at 4&deg;C or 25&deg;C; consult specific references for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatible; Y-site:",
"     </b>",
"     Bleomycin, carboplatin, carmustine, chlorpromazine, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone, diphenhydramine, doxorubicin, droperidol, etoposide, fludarabine, ifosfamide, mechlorethamine, methotrexate, mesna, metoclopramide, mitoxantrone, prochlorperazine, promethazine, teniposide, vinblastine, and vincristine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with acyclovir, ampicillin, aminophylline, furosemide, ganciclovir, lorazepam, methylprednisolone, and piperacillin",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orally disintegrating tablets, oral solution, oral tablets: Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy (FDA approved in ages &ge;4 years and adults); prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy (including cisplatin) (FDA approved in ages &ge;4 years and adults); prevention of nausea and vomiting associated with  radiotherapy (FDA approved in adults); prevention of postoperative nausea and vomiting (FDA approved in adults); has also been used in the treatment of hyperemesis gravidarum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Soluble Film (Zuplenz&reg;): Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (FDA approved in ages &ge;4 years and adults); prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy or radiotherapy (FDA approved in adults); prevention of postoperative nausea and vomiting (PONV) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Prevention of nausea and vomiting associated emetogenic cancer chemotherapy [including high-dose cisplatin (highly emetogenic)] (FDA approved in ages &ge;6 months and adults); prevention of postoperative nausea and vomiting (FDA approved in ages &ge;1 month and adults); has also been used in the treatment of hyperemesis gravidarum",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ondansetron may be confused with dolasetron, granisetron, palonosetron",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zofran&reg; may be confused with Zantac&reg;, Zosyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F203762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, cold sensation, dizziness, drowsiness, fatigue, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Gynecological disorder, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (&gt;2 times ULN), AST increased (&gt;2 times ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hypoxia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal hepatic function, anaphylactoid reactions, anaphylaxis, angina, angioedema, arrhythmia, atrial fibrillation, AV block, blindness (transient/following infusion; lasting &le;48 hours), blurred vision (transient/following infusion), bradycardia, cardiopulmonary arrest, dystonic reaction, electrocardiographic alterations (second-degree heart block and ST-segment depression), extrapyramidal symptoms, hepatic failure, hepatic necrosis, hepatitis, hypersensitivity reaction, hypokalemia, hypotension, oculogyric crisis, premature ventricular contractions (PVC), QT interval increased, seizure, shock, supraventricular tachycardia, syncope, tachycardia, torsade de pointes, vascular occlusive events, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ondansetron, other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists, or any component; concurrent use of apomorphine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients at risk of QT prolongation and/or ventricular arrhythmia, including patients with congenital long QT syndrome or other risk factors for QT prolongation [eg, medications known to prolong QT interval, electrolyte abnormalities (hypokalemia or hypomagnesemia), and cumulative high-dose anthracycline therapy]. Use with caution in patients allergic to other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists; cross-reactivity has been reported. Use with caution in patients with hepatic impairment; clearance is decreased and half-life is increased; dose recommendations provided for patients with severe hepatic impairment (Child-Pugh C). Does not stimulate gastric or intestinal peristalsis; may mask progressive ileus and/or gastric distension. When used for chemotherapy-related emesis, administration should be used on a scheduled basis, not on an \"as needed\" (PRN) basis, since data support the use of this drug only in the prevention of nausea and vomiting and not in the rescue of nausea and vomiting. Should only be used in the first 24-48 hours of chemotherapy. Data does not support any increased efficacy in delayed nausea and vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Profound hypotension and loss of consciousness have been reported with concurrent use of ondansetron and apomorphine; coadministration of these agents is contraindicated. QT interval prolongation and torsades de pointes have been reported with ondansetron; selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists, including ondansetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT), usually occurring 1-2 hours after I.V. administration. Single doses &gt;16 mg ondansetron I.V. are not recommended due to the potential for an increased risk of QT prolongation. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics), clinically relevant QT interval prolongation may occur resulting in torsade de pointes. A number of trials have shown that 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists produce QT interval prolongation to variable degrees.  Avoid use in patients with congenital long QT syndrome. ECG monitoring is recommended if used concurrently with other agents that prolong the QT interval or in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), CHF, or bradyarrhythmias.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Zofran&reg; solution contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of Zofran&reg; solution in neonates. Orally disintegrating tablets contain phenylalanine; use with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F203750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu, 2006). The use of ondansetron for the treatment of nausea and vomiting of pregnancy (NVP) has been evaluated. Although a significant increase in birth defects has not been described in case reports and some studies (Ferreira, 2012; Pasternak, 2013), other studies have shown a possible association with ondansetron exposure and adverse fetal events (Anderka, 2012; Einarson, 2004). Additional studies are needed to determine safety to the fetus, particularly during the first trimester. Based on available data, use is generally reserved for severe NVP (hyperemesis gravidarum) or when conventional treatments are not effective (ACOG, 2004; Koren, 2012; Levicheck, 2002; Tan, 2011). Because a dose-dependent QT-interval prolongation occurs with use, the manufacturer recommends ECG monitoring in patients with electrolyte abnormalities (which can be associated with some cases of NVP; Koren, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13786892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Closely monitor patients &lt;4 months of age; baseline ECG (if applicable); serum electrolytes (K/Mg); emesis episodes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 100%; nonlinear absorption occurs with increasing oral doses; Zofran&reg; ODT tablets are bioequivalent to Zofran&reg; tablets; absorption does not occur via oral mucosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Surgical patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-4 months: 3.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5-24 months: 2.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     3-12 years: 1.65 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents: Cancer patients: 4-18 years: 1.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 70% to 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Some first-pass metabolism; primarily by hydroxylation, followed by glucuronidation and sulfate conjugation; CYP1A2, CYP2D6, and CYP3A4 substrate; some demethylation occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 50% to 70% due to some first-pass metabolism; in cancer patients (adults) 85% to 87% bioavailability possibly related to changes in metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1-4 months: 6.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children 5 months to 12 years: 2.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3.5-5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to moderate hepatic impairment (Child-Pugh A-B): 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh C): 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine and feces; &lt;5% of the parent drug is recovered unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Surgical patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     1-4 months: 0.401 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     5-24 months: 0.581 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     3-12 years: 0.439 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents: Cancer patients 4-18 years: 0.599 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults (normal):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     19-40 years: 0.381 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     61-74 years: 0.319 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;75 years: 0.262 L/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/24/24965?source=see_link\">",
"      see \"Ondansetron: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This drug is given to prevent nausea and vomiting. May cause headache, drowsiness, or dizziness. Report immediately any chest pain or palpitations, persistent headache, respiratory difficulty, excessive drowsiness, fever, constipation, or diarrhea. Zuplenz&reg; (oral film): Place film on top of tongue and allow to dissolve. May swallow with or without liquid. Allow one film to dissolve before using another. Orally disintegrating tablets: Using dry hands, place tablet on tongue, and allow to dissolve. Swallow with saliva. If this medication is given by intravenous infusion, monitoring may be necessary. Report any pain/itching at infusion site.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F203685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (0.8 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If commercial oral solution is unavailable, a 0.8 mg/mL syrup may be made with ondansetron tablets, Ora-Plus&reg; (Paddock), and any of the the following syrups: Cherry syrup USP, Syrpalta&reg; (HUMCO), Ora-Sweet&reg; (Paddock), or Ora-Sweet&reg; Sugar-Free (Paddock). Crush ten 8 mg tablets in a mortar and reduce to a fine powder (flaking of the tablet coating occurs). Add 50 mL Ora-Plus&reg; in 5 mL increments, mixing thoroughly; mix while adding the chosen syrup in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with syrup, and add sufficient quantity of syrup to make 100 mL. Label \"shake well\" and \"refrigerate\". Stable for 42 days refrigerated (Trissel, 1996).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rectal suppositories: Calibrate a suppository mold for the base being used. Determine the displacement factor (DF) for ondansetron for the base being used (Fattibase&reg; = 1.1; Polybase&reg; = 0.6). Weigh the ondansetron tablet(s). Divide the tablet weight by the DF; this result is the weight of base displaced by the drug. Subtract the weight of base displaced from the calculated weight of base required for each suppository. Grind the ondansetron tablets in a mortar and reduce to a fine powder. Weigh out the appropriate weight of suppository base. Melt the base over a water bath (&lt;55&deg;C). Add the ondansetron powder to the suppository base and mix well. Pour the mixture into the suppository mold and cool. Stable for at least 30 days refrigerated (Tenjarla, 1998).",
"    </p>",
"    <div class=\"reference\">",
"     Tenjarla SN, Ward ES, and Fox JL, \"Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux Through Rabbit Rectal Membrane,\"",
"     <i>",
"      Int J Pharm Compound",
"     </i>",
"     , 1998, 2(1):83-8.",
"    </div>",
"    <div class=\"reference\">",
"     Trissel LA,",
"     <i>",
"      Trissel's Stability of Compounded Formulations",
"     </i>",
"     , Washington, DC: American Pharmaceutical Association, 1996.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al-Ansari K, Alomary S, Abdulateef H, et al, \"Metoclopramide Versus Ondansetron for the Treatment of Vomiting in Children With Acute Gastroenteritis,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2011, 53(2):156-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/21788756/pubmed\" id=\"21788756\" target=\"_blank\">",
"        21788756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetrics and Gynecology, \"ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(8):729-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/10326616/pubmed\" id=\"10326616\" target=\"_blank\">",
"        10326616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carden PA, Mitchell SL, Waters KD, et al, &ldquo;Prevention of Cyclophosphamide/Cytarabine-Induced Emesis With Ondansetron in Children With Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, 8(9):1531-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/2144019/pubmed\" id=\"2144019\" target=\"_blank\">",
"        2144019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Managing Acute Gastroenteritis Among Children: Oral Rehydration, Maintenance, and Nutritional Therapy,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-16):1-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeCamp LR, Byerley JS, Doshi N, et al, \"Use of Antiemetic Agents in Acute Gastroenteritis: A Systematic Review and Meta-analysis,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2008, 162(9):858-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/18762604/pubmed\" id=\"18762604\" target=\"_blank\">",
"        18762604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freedman SB, Adler M, Seshadri R, et al, \"Oral Ondansetron for Gastroenteritis in a Pediatric Emergency Department,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(16):1698-705.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/16625009/pubmed\" id=\"16625009\" target=\"_blank\">",
"        16625009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, \"Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holdsworth MT, Raisch DW, and Frost J, \"Acute and Delayed Nausea and Emesis Control in Pediatric Oncology Patients,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(4):931-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/16404740/pubmed\" id=\"16404740\" target=\"_blank\">",
"        16404740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li BU, Lefevre F, Chelimsky GG, et al, \"North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2008, 47(3):379-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/18728540/pubmed\" id=\"18728540\" target=\"_blank\">",
"        18728540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marty M, Pouillart P, Scholl S, et al, &ldquo;Comparison of the 5-hydroxytryptamine 3 (Serotonin) Antagonist Ondansetron (GR 38032F) With High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(12):816-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/2137902 /pubmed\" id=\"2137902 \" target=\"_blank\">",
"        2137902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mondick JT, Johnson BM, Haberer LJ, et al, \"Population Pharmacokinetics of Intravenous Ondansetron in Oncology and Surgical Patients Aged 1-48 Months,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2010, 66(1):77-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/19798490/pubmed\" id=\"19798490\" target=\"_blank\">",
"        19798490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer (MASCC), \"Antiemetic Guidelines,\" Updated April 2010. Available at file://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2010.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), \"Clinical Practice Guidelines in Oncology&trade;: Antiemesis,\" Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips RS, Gopaul S, Gibson F, et al, \"Antiemetic Medication for Prevention and Treatment of Chemotherapy Induced Nausea and Vomiting in Childhood,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (9):CD007786.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/20824866/pubmed\" id=\"20824866\" target=\"_blank\">",
"        20824866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pinkerton CR, Williams D, Wootton C, et al, &ldquo;5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Antagonist Ondansetron - An Effective Outpatient Antiemetic in Cancer Treatment,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1990, 65(8):822-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/2144721/pubmed\" id=\"2144721\" target=\"_blank\">",
"        2144721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roila F and Del Favero A, &ldquo;Ondansetron Clinical Pharmacokinetics,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 29(2):95-109.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/7586904 /pubmed\" id=\"7586904 \" target=\"_blank\">",
"        7586904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seynaeve C, Schuller J, Buser K, et al, &ldquo;Comparison of the Anti-emetic Efficacy of Different Doses of Ondansetron, Given as Either a Continuous Infusion or a Single Intravenous Dose, in Acute Cisplatin-Induced Emesis,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      1992, 66(1):192-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/1386245/pubmed\" id=\"1386245\" target=\"_blank\">",
"        1386245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spahr-Schopfer IA, Lerman J, Sikich N, et al, &ldquo;Pharmacokinetics of Intravenous Ondansetron in Healthy Children Undergoing Ear, Nose, and Throat Surgery,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 58(3):316-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/7554705 /pubmed\" id=\"7554705 \" target=\"_blank\">",
"        7554705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spector JI, Lester EP, Chevlen EM, et al, &ldquo;A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated With Cisplatin-Based Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 1998, 3(6):432-438.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27272/abstract-text/10388135/pubmed\" id=\"10388135\" target=\"_blank\">",
"        10388135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12659 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27272=[""].join("\n");
var outline_f26_40_27272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13246131\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203706\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203707\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060735\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060729\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203680\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203666\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060739\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203763\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060732\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060738\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203765\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203762\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060742\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060728\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060727\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203675\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203677\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786892\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060726\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060741\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060734\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203685\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=related_link\">",
"      Ondansetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/24/24965?source=related_link\">",
"      Ondansetron: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_40_27273="Boceprevir: Drug information";
var content_f26_40_27273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Boceprevir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"    see \"Boceprevir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12838380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Victrelis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13203002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Victrelis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12824576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12838435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of chronic hepatitis C (CHC):",
"     </b>",
"     Oral: 800 mg 3 times daily (in combination with peginterferon alfa and ribavirin).",
"     <i>",
"      Missed doses:",
"     </i>",
"     If a dose is missed, skip dose if it is &lt;2 hours before the next dose; if &ge;2 hours before next dose is due, take dose with food and resume normal dosing schedule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Treatment-naive patients without cirrhosis (interferon-responsive  [&ge;1-log",
"      <sub>",
"       10",
"      </sub>",
"      HCV-RNA decline in viral load] at week 4):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-4: Peginterferon alfa with concomitant ribavirin only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 5-8: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 9-24 (based on HCV-RNA results at week 8):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     or",
"     <b>",
"      detectable",
"     </b>",
"     at a level of &lt;100 units/mL: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA &ge;100 units/mL: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin. Recheck HCV-RNA at week 12. If HCV-RNA &ge;100 units/mL at week 12 (treatment futility), discontinue treatment (boceprevir, peginterferon alfa, and ribavirin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks &ge;24:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     at week 8 and week 24: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin for 4 additional weeks (through week 28)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     at Week 8 and",
"     <b>",
"      undetectable",
"     </b>",
"     at week 24:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     U.S. labeling: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin for 12 additional weeks (through week 36), followed by peginterferon alfa and ribavirin for additional 12 weeks (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Canadian labeling: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin for 4 additional weeks (through week 28), followed by peginterferon alfa and ribavirin for additional 20 weeks (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     at week 24: Discontinue treatment (boceprevir, peginterferon alfa, and ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Treatment-naive patients (interferon nonresponsive [&lt;0.5-log",
"      <sub>",
"       10",
"      </sub>",
"      HCV-RNA decline in viral load] at week 4):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer also recommends consideration of treatment of poor responders [&lt;1-log",
"     <sub>",
"      10",
"     </sub>",
"     HCV-RNA decline in viral load at week 4] in order to maximize rate of sustained virologic response (SVR):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-4: Peginterferon alfa with concomitant ribavirin only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 5-48: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Previously-treated patients without cirrhosis (partial response or  relapser):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Previously treated does not include prior treatment with boceprevir. \"Partial response\" includes patients with a &ge;2-log",
"     <sub>",
"      10",
"     </sub>",
"     HCV-RNA decrease by week 12, but a nonsustained virologic response thereafter. \"Relapser\" includes patients with an undetectable HCV-RNA upon completion of previous treatment, but with detectable HCV-RNA during the follow-up period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-4: Peginterferon alfa with concomitant ribavirin only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 5-8: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 9-24 (based on HCV-RNA results at week 8):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     or &lt;100 units/mL: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA &ge;100 units/mL: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin. Recheck HCV-RNA at week 12. If HCV-RNA &ge;100 units/mL at week 12, discontinue treatment (boceprevir, peginterferon alfa, and ribavirin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks &ge;24:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     at week 8 and week 24: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin for 12 additional weeks (through week 36)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     at Week 8 and",
"     <b>",
"      undetectable",
"     </b>",
"     at week 24: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin for 12 additional weeks (through week 36), followed by peginterferon alfa and ribavirin for additional 12 weeks (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     at week 24: Discontinue treatment (boceprevir, peginterferon alfa, and ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Previously treated patients with &lt;2-log",
"      <sub>",
"       10",
"      </sub>",
"      HCV-RNA decline by week 12 (prior null responders):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-4: Peginterferon alfa with concomitant ribavirin only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 5-8: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 9-24 (based on HCV-RNA results at week 8):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     or &lt;100 units/mL: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     : Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin. Recheck HCV-RNA at week 12. If HCV-RNA &ge;100 units/mL at week 12, discontinue treatment (boceprevir, peginterferon alfa, and ribavirin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks &ge;24:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     at week 24: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin for 24 additional weeks (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     at week 24: Discontinue treatment (boceprevir, peginterferon alfa, and ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cirrhosis, compensated:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-4: Peginterferon alfa with concomitant ribavirin only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 5-48: Boceprevir 800 mg 3 times daily with continued peginterferon alfa and ribavirin",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12838439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12838437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-severe impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD requiring hemodialysis: No dosage adjustment necessary. Not removed by hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12838436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild, moderate, or severe impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Decompensated cirrhosis: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); not approved for use in decompensated cirrhosis (safety/efficacy not established). Also refer to Peginterferon Alfa and Ribavirin individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12851246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Victrelis&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12838381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12838379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM255471.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM255471.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12838456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food. Doses should be taken approximately every 7-9 hours. Administer concurrently with peginterferon alfa and ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12824569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis C (CHC) genotype 1 (in combination with peginterferon alfa and ribavirin) in patients with compensated liver disease (including cirrhosis) who were previously untreated or have failed prior therapy with peginterferon alfa and ribavirin therapy including prior null responders, partial responders, and relapsers",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12838393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (55% to 58%), chills (33% to 34%), insomnia (30% to 34%), irritability (21% to 22%), dizziness (16% to 19%), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (22% to 27%), dry skin (18% to 22%), rash (16% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (43% to 46%), abnormal taste (35% to 44%), appetite decreased (25% to 26%), diarrhea (24% to 25%), vomiting (15% to 20%), xerostomia (11% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (45% to 50%), neutropenia (14% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (19% to 23%), weakness (15% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Hematologic: Thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative dermatitis, exfoliative rash, mouth ulceration, Stevens-Johnson syndrome, stomatitis, thromboembolic events, toxic skin eruption, toxicoderma, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12838387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to boceprevir or any component of the formulation; pregnancy; male partners of pregnant women",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Coadministration with CYP3A4/5 highly-dependent substrates (alfuzosin, cisapride, drospirenone, ergot derivatives, lovastatin, midazolam [oral], pimozide, sildenafil/tadalafil [when used for treatment of pulmonary arterial hypertension], simvastatin, triazolam) or strong CYP3A4/5 inducers (carbamazepine, phenobarbital, phenytoin, rifampin, St John&rsquo;s wort)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Refer to Peginterferon Alfa and Ribavirin monographs for individual product contraindications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Autoimmune hepatitis, hepatic decompensation (Child-Pugh class B or C); coadministration with amiodarone, astemizole, propafenone, quinidine, terfenadine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12838390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anemia: Has been reported with peginterferon alfa and ribavirin; addition of boceprevir is associated with further hemoglobin decreases. With anemia management, average hemoglobin decrease in clinical trials was ~1 g/dL with a median time to onset of 71 days. Dose modifications of peginterferon alfa and ribavirin were needed more often in patients also taking boceprevir. Complete blood counts should be obtained pretreatment and at weeks 2, 4, 8, and 12, as well as other times during treatment. Dose reduction of ribavirin therapy is recommended for the initial management of anemia if hemoglobin &lt;10 g/dL; permanent discontinuation of ribavirin treatment is recommended if hemoglobin &lt;8.5 g/dL. If ribavirin is permanently discontinued, boceprevir and peginterferon alfa must also be discontinued. In clinical trials comparing erythropoiesis-stimulating agents (ESAs) to ribavirin dose reduction for initial management of anemia during combination therapy, an increased risk of thromboembolic events were observed in patients receiving an ESA compared to the ribavirin dose reduction group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity:  Angioedema and urticaria have been reported with boceprevir, peginterferon alfa, and ribavirin combination therapy.  Discontinuation of combination therapy and institution of supportive measures may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenia: Has been reported with peginterferon alfa and ribavirin; addition of boceprevir is associated with a higher incidence of neutropenia. Complete blood counts should be obtained pretreatment and at weeks 2, 4, 8, and 12, as well as other times during treatment. May require dose reduction or interruption of peginterferon or ribavirin therapy. May be severe or life-threatening (rare); discontinuation of therapy may be necessary. If ribavirin and peginterferon alfa are permanently discontinued, boceprevir must also be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy: Combination therapy with ribavirin may cause birth defects; avoid pregnancy in females and female partners of male patients during therapy and for 6 months following treatment; two forms of effective contraception should be used. Combination therapy with ribavirin is contraindicated in pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Should only be used in combination with peginterferon alfa and ribavirin (do not use as monotherapy). Safety and efficacy have not been established in patients who have received organ transplants, have decompensated cirrhosis, or have been coinfected with hepatitis B or HIV. Efficacy has not been studied in patients who previously failed boceprevir therapy or therapy including another NS3/4A protease inhibitor for hepatitis C treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Poor responders: Patients who have less than 0.5-log",
"     <sub>",
"      10",
"     </sub>",
"     HCV-RNA decline at treatment week 4 with peginterferon alfa and ribavirin when",
"     <b>",
"      initiating",
"     </b>",
"     boceprevir therapy are predicted to have less than a 2-log",
"     <sub>",
"      10",
"     </sub>",
"     HCV-RNA decline by treatment week 12. Those poor responders treated with boceprevir will likely not have a sustained virologic response (SVR) and have a predisposition to viral resistance at treatment failure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F12851564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of BCRP, CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12858681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Boceprevir may increase the serum concentration of ALPRAZolam.  Management: In patients receiving boceprevir, consider lower alprazolam doses and monitor closely for symptoms of toxicity (including prolonged sedation and respiratory depression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Boceprevir may increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Astemizole: Boceprevir may increase the serum concentration of Astemizole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Boceprevir may increase the serum concentration of AtorvaSTATin.  Management: Limit the atorvastatin maximum adult dose to 40 mg daily in patients receiving boceprevir.  Monitor clinical response to ensure that the lowest necessary atorvastatin dose is used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Boceprevir may increase the serum concentration of Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Boceprevir may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Boceprevir may decrease the serum concentration of Buprenorphine. Boceprevir may increase the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Boceprevir may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Boceprevir may increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Boceprevir may decrease the serum concentration of Contraceptives (Estrogens).  Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone.  Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Boceprevir may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Boceprevir.  Management: Cyclosporine dose adjustments will likely be necessary when used together with boceprevir.  Monitor serum cyclosporine concentrations closely, and monitor patients for evidence of cyclosporine toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Boceprevir. Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desipramine: Boceprevir may increase the serum concentration of Desipramine.  Management: Consider lower doses of desipramine in patients treated with boceprevir and monitor for symptoms of desipramine toxicity (including dizziness, hypotension and syncope), due to a possible increase in desipramine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Boceprevir may increase the serum concentration of Digoxin.  Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrations, and titrate carefully due to a possible risk of elevated digoxin concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Boceprevir may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: Boceprevir may increase the serum concentration of Drospirenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Boceprevir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Boceprevir may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Boceprevir may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Boceprevir may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Escitalopram: Boceprevir may decrease the serum concentration of Escitalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Boceprevir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: Boceprevir may increase the serum concentration of Fluvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Boceprevir may increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Boceprevir.  Management: Limit maximum adult itraconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in itraconazole concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Boceprevir may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Boceprevir.  Management: Limit maximum adult ketoconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in ketoconazole concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Boceprevir may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Boceprevir may increase the serum concentration of Methadone. Boceprevir may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Boceprevir may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Boceprevir may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Boceprevir may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Boceprevir may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Boceprevir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Boceprevir may increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Boceprevir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Boceprevir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.  Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Boceprevir may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Boceprevir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Boceprevir may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Boceprevir may increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Boceprevir may increase the serum concentration of Sildenafil.  Management: Avoid sildenafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg every other day with close monitoring for sildenafil toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Boceprevir may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Boceprevir may increase the serum concentration of Sirolimus.  Management: Significant sirolimus dose reductions may be required if used with boceprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Boceprevir may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus doses will need to be substantially reduced, and the tacrolimus dosing interval will likely need to be prolonged with concurrent boceprevir. Follow tacrolimus concentrations closely and monitor patients for evidence of tacrolimus toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Boceprevir may increase the serum concentration of Tadalafil.  Management: Avoid tadalafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Tadalafil for erectile dysfunction should be limited to 10 mg every 72 hours with close monitoring for tadalafil toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Boceprevir may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Boceprevir may increase the serum concentration of TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Boceprevir may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Boceprevir may increase the serum concentration of Vardenafil.  Management: Limit vardenafil maximum dose to 2.5 mg every 24 hours and monitor closely for symptoms of vardenafil toxicity (including hypotension, visual changes, syncope, and priapism) during treatment with boceprevir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Boceprevir may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Boceprevir may decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12838383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B / X (in combination with ribavirin) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12838384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed with boceprevir in animal reproduction studies; however, boceprevir must not be used as monotherapy (must be used in combination with peginterferon alfa and ribavirin).  Adverse events have been observed with ribavirin in animal reproduction studies. Use of ribavirin is contraindicated in pregnant women and males whose female partners are pregnant. A negative pregnancy test is required before initiation of therapy and pregnancy testing should be conducted monthly during treatment and for 6 months after therapy has ended. Women of childbearing potential and males must use at least 2 effective forms of contraception during treatment and continue contraceptive measures for at least 6 months after completion of therapy. One of the two forms of effective contraception may be a combined oral contraceptive product with at least 1 mg of norethindrone; oral contraceptives with &lt;1 mg of norethindrone and other forms of hormonal contraception are contraindicated because they have not been studied.  If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure. If pregnancy occurs during use or within 6 months after treatment, report to the ribavirin pregnancy registry (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12838385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12838386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if boceprevir is excreted into breast milk. According to the manufacturer, due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Breast-feeding is not linked to the spread of hepatitis C virus; however, if nipples are cracked or bleeding, breast-feeding is not recommended (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12838441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food. The type or timing of a meal is not important as long as dose is taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Victrelis Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (12): $237.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12838458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CBC with differential at baseline, followed by CBC at weeks 2, 4, 8 and 12, then periodically (and when clinically indicated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum HCV RNA at baseline, weeks 4, 8, 12 and 24, end of treatment, during treatment follow up, and when clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pretreatment and monthly pregnancy test up to 6 months following discontinuation of therapy for women of childbearing age",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12838419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment futility: HCV-RNA &ge;100 units/mL at treatment week 12 or confirmed, detectable HCV-RNA at treatment week 24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rapid virological response (RVR): Absence of detectable HCV RNA after 4 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Early viral response (EVR): &ge;2-log decrease in HCV RNA after 8-12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     End of treatment response (ETR): Absence of detectable HCV RNA at end of the recommended treatment period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained treatment response (STR): Absence of HCV RNA in the serum 6 months following completion of full treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained virologic response (SVR): Plasma HCV RNA &lt;25 units/mL at follow up week 24",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Victrelis (AU, BE, CH, CZ, DE, DK, EE, FR, GB, IE, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12838417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds reversibly to nonstructural protein 3 (NS 3) serine protease and inhibits replication of the hepatitis C virus. Considered a direct-acting antiviral treatment for HCV, also called a specifically targeted antiviral therapy for HCV (STAT-C).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12838420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Food (type or timing is not important) enhances absorption by up to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~772 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily hepatic via aldo-ketoreductase pathway to inactive metabolites. Also some oxidative CYP 3A4/5 metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Plasma: Adults: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (79%); urine (9%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bacon BR, Gordon SC, Lawitz E, et al, &ldquo;Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 201, 364(13):1207-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/21449784/pubmed\" id=\"21449784\" target=\"_blank\">",
"        21449784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berman K and Kwo PY, &ldquo;Boceprevir, an NS3 Protease Inhibitor of HCV,&rdquo;",
"      <i>",
"       Clin Liver Dis",
"      </i>",
"      , 2009, 13(3):429-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/19628159/pubmed\" id=\"19628159\" target=\"_blank\">",
"        19628159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, &ldquo;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghosal A, Yuan Y, Tong W, et al, &ldquo;Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor,&rdquo;",
"      <i>",
"       Drug Metab Disposition",
"      </i>",
"      , 2011, 39(3):510-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/21123164/pubmed\" id=\"21123164\" target=\"_blank\">",
"        21123164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(23):2444-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/17151366/pubmed\" id=\"17151366\" target=\"_blank\">",
"        17151366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwo PY, Lawitz EJ, McCone J, et al, &ldquo;Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Na&iuml;ve Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9742):705-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/20692693/pubmed\" id=\"20692693\" target=\"_blank\">",
"        20692693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauer GM and Walker BD, &ldquo;Hepatitis C Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(1):41-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/11439948/pubmed\" id=\"11439948\" target=\"_blank\">",
"        11439948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poordad F, McCone J Jr, Bacon BR, et al, &ldquo;Boceprevir for Untreated Chronic HCV Genotype 1 Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(13):1195-206.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/21449783/pubmed\" id=\"21449783\" target=\"_blank\">",
"        21449783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Susser S, Welsch C, Wang Y, et al, &ldquo;Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(6):1709-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/40/27273/abstract-text/19787809/pubmed\" id=\"19787809\" target=\"_blank\">",
"        19787809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16492 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27273=[""].join("\n");
var outline_f26_40_27273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838380\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203002\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824576\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838435\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838439\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838437\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838436\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851246\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838381\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838379\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838456\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824569\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838393\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838387\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838390\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851564\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858681\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838383\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838384\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838385\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838386\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838441\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322900\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838458\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838419\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276712\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838417\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838420\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=related_link\">",
"      Boceprevir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_40_27274="Bowel resection and reapprox A";
var content_f26_40_27274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52269%7EOBGYN%2F61001%7EOBGYN%2F73759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52269%7EOBGYN%2F61001%7EOBGYN%2F73759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approximation of posterior seromuscular layer during bowel resection and reanastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Posterior mucosal running suture and mucosal suture continued anteriorly during bowel resection and reanastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Anterior seromuscular imbricating layer during bowel resection and reanastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27274=[""].join("\n");
var outline_f26_40_27274=null;
var title_f26_40_27275="Diagnostic criteria aCML";
var content_f26_40_27275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for atypical chronic myeloid leukemia, BCR-ABL negative (aCML)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Peripheral blood leukocytosis (WBC &ge;13x10",
"        <sup>",
"         9",
"        </sup>",
"        /L) due to increased numbers of neutrophils and their precursors with prominent dysgranulopoiesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No Ph chromosome or",
"        <em>",
"         BCR-ABL1",
"        </em>",
"        fusion gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No rearrangement of",
"        <em>",
"         PDGFRA",
"        </em>",
"        or",
"        <em>",
"         PDGFRB",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophil precursors (promyelocytes, myelocytes, metamyelocytes) &ge;10 percent of leukocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal absolute basophilia; basophils usually &lt;2 percent of leukocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No or minimal absolute monocytosis; monocytes &lt;10 percent of leukocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercellular bone marrow with granulocytic proliferation and granulocytic dysplasia, with or without dysplasia in the erythroid and megakaryocytic lineages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less than 20 percent blasts in the blood and in the bone marrow",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2008. Reproduced with permission. Copyright &copy; 2008 IARC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27275=[""].join("\n");
var outline_f26_40_27275=null;
var title_f26_40_27276="Lymphomatoid papulosis differential";
var content_f26_40_27276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" style=\"width: 95.49%; height: 426px;\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        LyP",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic ALCL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mycosis fungoides",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pityriasis lichenoides",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arthropod bite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Scabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Clinical",
"       </td>",
"       <td>",
"        Self-healing papulonodular skin lesions",
"       </td>",
"       <td>",
"        Frequent secondary skin lesions, lymphadenopathy B symptoms",
"       </td>",
"       <td>",
"        Scaling erythematous patches, plaques, tumors, +/- lymphadenopathy",
"       </td>",
"       <td>",
"        Scaling erythematous hemorrhagic lesions",
"       </td>",
"       <td>",
"        Exposure",
"       </td>",
"       <td>",
"        <p>",
"         Itchy lesions",
"        </p>",
"        <p>",
"         Responds well to scabies treatment",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Histopathology/immunophenotype",
"       </td>",
"       <td>",
"        Atypical CD30, CD4+ cells surrounded by inflammatory cells",
"       </td>",
"       <td>",
"        <p>",
"         Lack of epidermotropic cerebriform cells",
"        </p>",
"        <p>",
"         ALK+, EMA+; ALK- in patients over 30",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Epidermotropism of cerebriform cells",
"        </p>",
"        <p>",
"         CD30+ with large cell transformation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Interface dermatitis",
"        </p>",
"        <p>",
"         CD8 &gt;CD4, few CD30+ cells",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Punctum, insect parts",
"        </p>",
"        <p>",
"         Polymorphous",
"        </p>",
"        <p>",
"         Inflammation",
"        </p>",
"        <p>",
"         CD30+ cells may be present",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Presence of mite",
"        </p>",
"        <p>",
"         CD30+ cells and B cells present",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Genetics",
"       </td>",
"       <td>",
"        Clonal in 60 percent; aneuploidy of type A; lack of t(2;5)",
"       </td>",
"       <td>",
"        <p>",
"         t(2;5) often present",
"        </p>",
"        <p>",
"         No IRF4 translocation",
"        </p>",
"        <p>",
"         Clonal TCR rearrangement",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lack of t(2;5)",
"        </p>",
"        <p>",
"         Complex karyotype, clonal or oligoclonal TCR&nbsp;&nbsp;rearrangement",
"        </p>",
"       </td>",
"       <td>",
"        Clonal TCR rearrangement&nbsp;in 50 percent",
"       </td>",
"       <td>",
"        No abnormalities",
"       </td>",
"       <td>",
"        No abnormalities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ALK: anaplastic lymphoma kinase; EMA: epithelial membrane antigen; TCR: T cell receptor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27276=[""].join("\n");
var outline_f26_40_27276=null;
var title_f26_40_27277="Evaluation myoclonus";
var content_f26_40_27277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of myoclonus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Part one:",
"        </p>",
"        <p>",
"         History, physical examination, and clinical syndrome classification",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Full history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mode of myoclonus onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Presence of other neurological problems including seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drug or toxin exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other medical problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Distribution (may be focal, segmental, multifocal, hemi, generalized)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Temporal profile (includes rhythmic or irregular)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Continuous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Intermittent (sporadic or trains)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Activation profile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Rest (Spontaneous myoclonus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Voluntary movement (Action myoclonus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Reflex stimuli (any combination of touch, light, sound, or muscle stretch)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Determine major clinical syndrome category:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Physiologic (normal subjects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Essential (primary symptom, nonprogressive history)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Epileptic (associated with a chronic seizure disorder or syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Symptomatic (secondary, but not defined by occurrence of seizures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Part two:",
"        </p>",
"        <p>",
"         Ancillary testing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid antibodies and function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug and toxin screen (if history suggests)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spine imaging (if focal or segmental)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrospinal fluid analysis (eg, for infectious and inflammatory disorders, prion disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Part three:",
"        </p>",
"        <p>",
"         Clinical neurophysiology testing to determine physiologic classification (see text)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electroencephalography (EEG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surface electromyography (EMG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simultaneous electroencephalography-electromyography polygraphy (EEG-EMG polygraphy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatosensory evoked potentials (SEPs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jerk-locked back-averaging of EEG transients and/or SEPs to EMG discharges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long latency EMG responses to peripheral nerve stimulation (eg, C reflex)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Part four:",
"        </p>",
"        <p>",
"         Testing for uncommon and rare diagnoses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        If not otherwise ruled out, the following should be considered:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Body imaging for occult cancer, even in the absence of paraneoplastic antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Evaluation for malabsorption disorders such as Celiac sprue and Whipple disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Enzyme assays for neuraminidase deficiency (sialidosis) and biotinidase deficiency (multiple carboxylase deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Evaluation for Wilson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Evaluation for ataxia-telangiectasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Genetic testing (and tissue biopsy if indicated) for inherited disorders, such as Unverricht-Lundborg disease (EPM1 gene), Lafora body disease (EPM2A and EPM2B genes), neuronal ceroid lipofuscinosis, and Huntington disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Evaluation for mitochondrial disorders, including serum lactate, muscle biopsy, and genetic testing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Caviness, JN, Brown, P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27277=[""].join("\n");
var outline_f26_40_27277=null;
var title_f26_40_27278="Conditioning regimens dose intensities";
var content_f26_40_27278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F87814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F87814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Dose intensity of selected conditioning regimens used for allogeneic hematopoietic cell transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BU: busulfan; CY: cyclophosphamide; TBI: total body irradiation; Flu: fludarabine (various dosing schedules); AraC: cytosine arabinoside; ATG: antithymocyte globulin (or thymoglobulin); 131I: anti-CD45 antibody conjugated to 131I; GVT: graft versus tumor.",
"     <br>",
"      * \"High-dose\" TBI (800 to 1320 cGy).",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       \"Low-dose\" TBI (200 to 400 cGy).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116:4762. Copyright &copy; 2010 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27278=[""].join("\n");
var outline_f26_40_27278=null;
var title_f26_40_27279="Padded foot splint";
var content_f26_40_27279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resting padded foot splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A splint such as the one pictured here may be helpful for symptoms of plantar fasciitis or plantar fascia rupture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_40_27279=[""].join("\n");
var outline_f26_40_27279=null;
